Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 77 | 2023 | 454 | 14.990 |
Why?
|
Immunotherapy | 64 | 2023 | 627 | 10.440 |
Why?
|
Neoplasms | 68 | 2023 | 2889 | 8.810 |
Why?
|
T-Lymphocytes | 64 | 2022 | 1195 | 7.740 |
Why?
|
Tumor Microenvironment | 41 | 2022 | 415 | 7.320 |
Why?
|
CD8-Positive T-Lymphocytes | 44 | 2022 | 556 | 6.730 |
Why?
|
Lymphocyte Activation | 56 | 2018 | 727 | 5.100 |
Why?
|
Skin Neoplasms | 24 | 2023 | 541 | 4.260 |
Why?
|
Signal Transduction | 47 | 2020 | 3233 | 4.120 |
Why?
|
Antigens, Neoplasm | 27 | 2018 | 324 | 3.310 |
Why?
|
Gastrointestinal Microbiome | 9 | 2022 | 451 | 3.160 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 12 | 2020 | 123 | 3.030 |
Why?
|
T-Lymphocyte Subsets | 21 | 2017 | 272 | 3.000 |
Why?
|
Dendritic Cells | 19 | 2020 | 424 | 2.910 |
Why?
|
Programmed Cell Death 1 Receptor | 20 | 2022 | 159 | 2.880 |
Why?
|
Receptors, Antigen, T-Cell | 35 | 2014 | 371 | 2.860 |
Why?
|
Clonal Anergy | 11 | 2013 | 30 | 2.770 |
Why?
|
Immunity, Innate | 16 | 2016 | 405 | 2.700 |
Why?
|
beta Catenin | 8 | 2019 | 250 | 2.680 |
Why?
|
Mice | 121 | 2022 | 11313 | 2.580 |
Why?
|
Cancer Vaccines | 20 | 2019 | 156 | 2.540 |
Why?
|
Interferon-gamma | 30 | 2020 | 444 | 2.400 |
Why?
|
Antineoplastic Agents, Immunological | 9 | 2020 | 185 | 2.360 |
Why?
|
Animals | 150 | 2022 | 26518 | 2.360 |
Why?
|
Antibodies, Monoclonal | 29 | 2023 | 1376 | 2.360 |
Why?
|
Membrane Proteins | 10 | 2019 | 1194 | 2.230 |
Why?
|
Antineoplastic Agents | 23 | 2023 | 2351 | 2.050 |
Why?
|
Neoplasms, Experimental | 11 | 2020 | 269 | 2.010 |
Why?
|
Humans | 204 | 2023 | 86281 | 1.960 |
Why?
|
Interleukin-2 | 29 | 2017 | 249 | 1.880 |
Why?
|
Chemokine CXCL10 | 3 | 2022 | 17 | 1.860 |
Why?
|
Tumor Escape | 8 | 2018 | 49 | 1.850 |
Why?
|
B7-H1 Antigen | 16 | 2020 | 250 | 1.830 |
Why?
|
Interferon Type I | 5 | 2015 | 175 | 1.820 |
Why?
|
Melanoma, Experimental | 11 | 2018 | 103 | 1.770 |
Why?
|
CD28 Antigens | 13 | 2013 | 88 | 1.740 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2021 | 2434 | 1.730 |
Why?
|
PTEN Phosphohydrolase | 5 | 2019 | 128 | 1.680 |
Why?
|
Ipilimumab | 10 | 2023 | 58 | 1.680 |
Why?
|
Interleukin-12 | 16 | 2019 | 108 | 1.670 |
Why?
|
T-Lymphocytes, Regulatory | 7 | 2013 | 295 | 1.650 |
Why?
|
Cytotoxicity, Immunologic | 20 | 2020 | 213 | 1.650 |
Why?
|
Antigens, CD | 24 | 2017 | 457 | 1.640 |
Why?
|
Early Growth Response Protein 2 | 3 | 2017 | 17 | 1.500 |
Why?
|
B7-1 Antigen | 17 | 2009 | 75 | 1.480 |
Why?
|
Cytokines | 19 | 2022 | 775 | 1.440 |
Why?
|
Microbiota | 6 | 2022 | 378 | 1.410 |
Why?
|
Mice, Transgenic | 35 | 2020 | 1537 | 1.410 |
Why?
|
Mice, Inbred C57BL | 38 | 2020 | 3087 | 1.400 |
Why?
|
Antigen-Presenting Cells | 17 | 2016 | 139 | 1.390 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2020 | 589 | 1.360 |
Why?
|
Mice, Knockout | 28 | 2017 | 1918 | 1.310 |
Why?
|
Cell Proliferation | 15 | 2020 | 1571 | 1.300 |
Why?
|
T-Lymphocytes, Cytotoxic | 23 | 2007 | 314 | 1.270 |
Why?
|
Mast-Cell Sarcoma | 11 | 2001 | 15 | 1.270 |
Why?
|
Immunotherapy, Adoptive | 4 | 2017 | 170 | 1.270 |
Why?
|
Immune Tolerance | 10 | 2018 | 337 | 1.190 |
Why?
|
Cell Line, Tumor | 22 | 2020 | 2421 | 1.180 |
Why?
|
Cross-Priming | 6 | 2018 | 48 | 1.150 |
Why?
|
Antigens, Differentiation | 13 | 2009 | 141 | 1.090 |
Why?
|
CD4-Positive T-Lymphocytes | 11 | 2014 | 425 | 1.090 |
Why?
|
CTLA-4 Antigen | 19 | 2023 | 135 | 1.060 |
Why?
|
Interferons | 2 | 2016 | 132 | 1.050 |
Why?
|
DNA-Binding Proteins | 12 | 2019 | 1208 | 1.050 |
Why?
|
Immunoconjugates | 9 | 2002 | 106 | 1.050 |
Why?
|
Homeostasis | 5 | 2012 | 408 | 1.010 |
Why?
|
ras Proteins | 4 | 2014 | 128 | 1.010 |
Why?
|
Gene Expression Profiling | 12 | 2020 | 1381 | 1.010 |
Why?
|
T-Lymphocytes, Helper-Inducer | 16 | 1998 | 132 | 0.990 |
Why?
|
Antibodies, Monoclonal, Humanized | 12 | 2023 | 929 | 0.990 |
Why?
|
Adaptive Immunity | 7 | 2016 | 164 | 0.970 |
Why?
|
Oximes | 3 | 2019 | 15 | 0.950 |
Why?
|
Antigens, Surface | 7 | 2009 | 101 | 0.940 |
Why?
|
Anti-Bacterial Agents | 3 | 2019 | 739 | 0.920 |
Why?
|
Sulfonamides | 4 | 2019 | 299 | 0.910 |
Why?
|
Kidney Neoplasms | 7 | 2022 | 620 | 0.900 |
Why?
|
Th1 Cells | 11 | 2007 | 164 | 0.900 |
Why?
|
Dermatitis | 1 | 2022 | 32 | 0.870 |
Why?
|
Wilms Tumor | 1 | 2022 | 38 | 0.860 |
Why?
|
Bifidobacterium | 3 | 2016 | 16 | 0.840 |
Why?
|
Hot Temperature | 1 | 2022 | 206 | 0.820 |
Why?
|
Up-Regulation | 7 | 2013 | 710 | 0.800 |
Why?
|
Interferon-beta | 5 | 2016 | 125 | 0.790 |
Why?
|
Neovascularization, Pathologic | 4 | 2014 | 352 | 0.770 |
Why?
|
Adaptor Proteins, Signal Transducing | 7 | 2016 | 302 | 0.770 |
Why?
|
Farnesyltranstransferase | 2 | 2012 | 6 | 0.760 |
Why?
|
Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2 | 2017 | 15 | 0.760 |
Why?
|
Cell Differentiation | 12 | 2014 | 1456 | 0.760 |
Why?
|
Immunity, Cellular | 4 | 2022 | 177 | 0.750 |
Why?
|
Treatment Outcome | 28 | 2020 | 7949 | 0.750 |
Why?
|
Diacylglycerol Kinase | 2 | 2012 | 5 | 0.750 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2020 | 14 | 0.740 |
Why?
|
p21-Activated Kinases | 1 | 2020 | 15 | 0.740 |
Why?
|
Mutation | 9 | 2020 | 3952 | 0.740 |
Why?
|
DNA Repair | 1 | 2022 | 356 | 0.730 |
Why?
|
Genetic Heterogeneity | 1 | 2020 | 62 | 0.730 |
Why?
|
Flow Cytometry | 15 | 2016 | 679 | 0.730 |
Why?
|
Apoptosis | 8 | 2018 | 1678 | 0.720 |
Why?
|
Colitis | 1 | 2022 | 236 | 0.710 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 315 | 0.710 |
Why?
|
Psoriasis | 1 | 2022 | 239 | 0.710 |
Why?
|
Membrane Glycoproteins | 14 | 2009 | 428 | 0.700 |
Why?
|
Female | 76 | 2023 | 44405 | 0.700 |
Why?
|
Chemotaxis, Leukocyte | 2 | 2017 | 37 | 0.700 |
Why?
|
Peptides | 12 | 2018 | 639 | 0.690 |
Why?
|
Graft Rejection | 12 | 2018 | 1064 | 0.680 |
Why?
|
Gene Expression | 7 | 2016 | 1281 | 0.680 |
Why?
|
Enzyme Inhibitors | 4 | 2014 | 632 | 0.680 |
Why?
|
Leukocytes, Mononuclear | 6 | 2018 | 196 | 0.670 |
Why?
|
Killer Cells, Natural | 3 | 2016 | 267 | 0.670 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 266 | 0.670 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 18 | 0.660 |
Why?
|
Mycoplasma | 3 | 2008 | 4 | 0.660 |
Why?
|
Angiogenesis Inhibitors | 5 | 2015 | 309 | 0.660 |
Why?
|
Adult | 43 | 2022 | 25577 | 0.650 |
Why?
|
Mycoplasma Infections | 3 | 2008 | 8 | 0.650 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 199 | 0.640 |
Why?
|
Mice, Inbred DBA | 20 | 2005 | 148 | 0.640 |
Why?
|
Neoplasm Metastasis | 18 | 2020 | 1056 | 0.630 |
Why?
|
Immune Evasion | 1 | 2018 | 33 | 0.630 |
Why?
|
Oncogenes | 1 | 2018 | 88 | 0.630 |
Why?
|
Phosphorylation | 10 | 2018 | 1101 | 0.620 |
Why?
|
DNA | 5 | 2022 | 1293 | 0.620 |
Why?
|
Adenoviridae | 7 | 2011 | 345 | 0.600 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2017 | 41 | 0.600 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2014 | 138 | 0.600 |
Why?
|
Male | 60 | 2023 | 40860 | 0.600 |
Why?
|
Immunity | 6 | 2020 | 134 | 0.600 |
Why?
|
Chemokines | 4 | 2013 | 72 | 0.600 |
Why?
|
Thymus Gland | 3 | 2009 | 195 | 0.590 |
Why?
|
Carcinoma, Renal Cell | 7 | 2006 | 425 | 0.590 |
Why?
|
Middle Aged | 47 | 2023 | 24957 | 0.570 |
Why?
|
Nucleotides, Cyclic | 2 | 2015 | 10 | 0.570 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 54 | 0.570 |
Why?
|
Recombinant Proteins | 12 | 2009 | 1014 | 0.570 |
Why?
|
Lymphopenia | 3 | 2012 | 28 | 0.560 |
Why?
|
Inflammasomes | 1 | 2016 | 23 | 0.560 |
Why?
|
Macrophages | 7 | 2022 | 554 | 0.550 |
Why?
|
Cytoplasmic Granules | 2 | 2006 | 94 | 0.550 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2018 | 376 | 0.550 |
Why?
|
Receptor, Interferon alpha-beta | 2 | 2014 | 20 | 0.540 |
Why?
|
Interleukin-4 | 9 | 2007 | 127 | 0.540 |
Why?
|
Clone Cells | 16 | 2020 | 213 | 0.540 |
Why?
|
Aged | 40 | 2022 | 18353 | 0.530 |
Why?
|
Glucose | 3 | 2008 | 637 | 0.530 |
Why?
|
Quinazolines | 2 | 2016 | 220 | 0.520 |
Why?
|
Immunomodulation | 4 | 2020 | 55 | 0.520 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 3 | 2012 | 115 | 0.520 |
Why?
|
Gene Expression Regulation | 9 | 2016 | 1917 | 0.520 |
Why?
|
H-2 Antigens | 4 | 2003 | 58 | 0.510 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 645 | 0.510 |
Why?
|
Biomarkers, Tumor | 13 | 2022 | 1461 | 0.500 |
Why?
|
Aged, 80 and over | 24 | 2021 | 6481 | 0.500 |
Why?
|
RNA Processing, Post-Transcriptional | 2 | 2007 | 105 | 0.490 |
Why?
|
Ascites | 3 | 2018 | 55 | 0.480 |
Why?
|
Repressor Proteins | 1 | 2017 | 403 | 0.480 |
Why?
|
Cell Movement | 7 | 2015 | 756 | 0.480 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 7 | 2015 | 376 | 0.480 |
Why?
|
Lymphoma, Follicular | 2 | 2023 | 70 | 0.470 |
Why?
|
HLA-A2 Antigen | 5 | 2018 | 31 | 0.460 |
Why?
|
Th2 Cells | 6 | 2007 | 146 | 0.450 |
Why?
|
Neoplasm Proteins | 5 | 2009 | 532 | 0.450 |
Why?
|
Benzodioxoles | 1 | 2012 | 16 | 0.450 |
Why?
|
Lymphocyte Depletion | 2 | 2014 | 97 | 0.450 |
Why?
|
Mitogen-Activated Protein Kinases | 3 | 2003 | 222 | 0.450 |
Why?
|
Tumor Cells, Cultured | 18 | 2009 | 1040 | 0.440 |
Why?
|
Blotting, Western | 5 | 2015 | 781 | 0.440 |
Why?
|
src-Family Kinases | 1 | 2012 | 74 | 0.440 |
Why?
|
Wnt Signaling Pathway | 3 | 2019 | 89 | 0.440 |
Why?
|
Phosphoproteins | 3 | 2010 | 253 | 0.440 |
Why?
|
Down-Regulation | 4 | 2010 | 504 | 0.440 |
Why?
|
Genetic Engineering | 2 | 2016 | 114 | 0.440 |
Why?
|
Lymphocyte Subsets | 2 | 2011 | 64 | 0.440 |
Why?
|
Cells, Cultured | 11 | 2014 | 2810 | 0.440 |
Why?
|
Quinolones | 3 | 2012 | 60 | 0.430 |
Why?
|
Disease Models, Animal | 7 | 2019 | 2227 | 0.430 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 7 | 2021 | 877 | 0.430 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2021 | 137 | 0.420 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 153 | 0.420 |
Why?
|
Coxsackie and Adenovirus Receptor-Like Membrane Protein | 4 | 2014 | 11 | 0.410 |
Why?
|
Immunologic Memory | 3 | 2017 | 152 | 0.410 |
Why?
|
Calcium | 7 | 2004 | 1148 | 0.410 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 4 | 2018 | 44 | 0.410 |
Why?
|
Transfection | 11 | 2015 | 895 | 0.400 |
Why?
|
Phospholipase C gamma | 1 | 2010 | 15 | 0.400 |
Why?
|
Isoenzymes | 2 | 2009 | 271 | 0.390 |
Why?
|
Gene Deletion | 2 | 2013 | 328 | 0.390 |
Why?
|
Protein Kinase Inhibitors | 3 | 2014 | 589 | 0.390 |
Why?
|
Drug Administration Schedule | 7 | 2019 | 916 | 0.390 |
Why?
|
CD3 Complex | 12 | 2007 | 135 | 0.390 |
Why?
|
Protein Kinase C | 2 | 2009 | 270 | 0.380 |
Why?
|
Italy | 9 | 2023 | 106 | 0.380 |
Why?
|
Clinical Trials as Topic | 11 | 2019 | 1168 | 0.370 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 3 | 2009 | 189 | 0.370 |
Why?
|
Oncolytic Virotherapy | 2 | 2022 | 41 | 0.370 |
Why?
|
Proto-Oncogene Proteins c-kit | 4 | 2015 | 79 | 0.370 |
Why?
|
Serine Endopeptidases | 3 | 2006 | 145 | 0.370 |
Why?
|
Immunologic Factors | 4 | 2020 | 170 | 0.370 |
Why?
|
Immunological Synapses | 1 | 2009 | 5 | 0.360 |
Why?
|
Nuclear Proteins | 3 | 2004 | 694 | 0.350 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 1958 | 0.350 |
Why?
|
CD8 Antigens | 4 | 2005 | 82 | 0.350 |
Why?
|
Dacarbazine | 2 | 2014 | 102 | 0.350 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2009 | 41 | 0.350 |
Why?
|
Combined Modality Therapy | 10 | 2020 | 1680 | 0.350 |
Why?
|
In Vitro Techniques | 10 | 2012 | 987 | 0.340 |
Why?
|
Red-Cell Aplasia, Pure | 1 | 2008 | 5 | 0.340 |
Why?
|
B-Lymphocytes | 6 | 2018 | 724 | 0.340 |
Why?
|
Indoles | 3 | 2014 | 318 | 0.340 |
Why?
|
CD40 Antigens | 3 | 2023 | 43 | 0.340 |
Why?
|
Adoptive Transfer | 9 | 2016 | 168 | 0.340 |
Why?
|
Cytotoxicity Tests, Immunologic | 3 | 2006 | 44 | 0.330 |
Why?
|
Cell Cycle | 3 | 2009 | 502 | 0.330 |
Why?
|
Cytological Techniques | 2 | 2006 | 30 | 0.330 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2005 | 71 | 0.330 |
Why?
|
Neoplasm Transplantation | 10 | 2009 | 391 | 0.330 |
Why?
|
Base Sequence | 8 | 2013 | 2329 | 0.330 |
Why?
|
Transduction, Genetic | 5 | 2013 | 153 | 0.330 |
Why?
|
Receptors, Virus | 4 | 2011 | 74 | 0.320 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2008 | 70 | 0.320 |
Why?
|
Salvage Therapy | 2 | 2010 | 232 | 0.320 |
Why?
|
Ciprofloxacin | 1 | 2008 | 28 | 0.320 |
Why?
|
Neoplasm Staging | 8 | 2019 | 1932 | 0.320 |
Why?
|
Epitopes | 5 | 2022 | 255 | 0.320 |
Why?
|
Cell Culture Techniques | 6 | 2008 | 187 | 0.310 |
Why?
|
Mice, Inbred BALB C | 14 | 2016 | 1047 | 0.310 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2007 | 36 | 0.310 |
Why?
|
Proteins | 4 | 2008 | 777 | 0.310 |
Why?
|
Sirolimus | 3 | 2018 | 169 | 0.310 |
Why?
|
Receptors, Death Domain | 1 | 2007 | 3 | 0.310 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2010 | 878 | 0.310 |
Why?
|
Trans-Activators | 2 | 2000 | 429 | 0.300 |
Why?
|
Pyrimidines | 3 | 2015 | 370 | 0.300 |
Why?
|
Prognosis | 7 | 2021 | 3669 | 0.300 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 25 | 0.300 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 3 | 2007 | 101 | 0.300 |
Why?
|
Nucleotidyltransferases | 3 | 2016 | 29 | 0.300 |
Why?
|
Cell Division | 9 | 2013 | 696 | 0.300 |
Why?
|
Cyclosporine | 2 | 2020 | 234 | 0.300 |
Why?
|
Real-Time Polymerase Chain Reaction | 3 | 2021 | 272 | 0.300 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2013 | 321 | 0.290 |
Why?
|
Immunosuppressive Agents | 5 | 2010 | 977 | 0.290 |
Why?
|
Antigen Presentation | 6 | 2013 | 209 | 0.290 |
Why?
|
Blood Proteins | 2 | 2004 | 144 | 0.290 |
Why?
|
Apoptosis Regulatory Proteins | 6 | 2010 | 199 | 0.290 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2016 | 1305 | 0.290 |
Why?
|
Ascitic Fluid | 1 | 2006 | 37 | 0.280 |
Why?
|
Immunophenotyping | 6 | 2006 | 211 | 0.280 |
Why?
|
Recombination, Genetic | 2 | 2007 | 439 | 0.280 |
Why?
|
Ligands | 6 | 2015 | 433 | 0.280 |
Why?
|
Abatacept | 9 | 2002 | 83 | 0.280 |
Why?
|
Radiosurgery | 2 | 2020 | 272 | 0.280 |
Why?
|
Uveal Neoplasms | 2 | 2016 | 11 | 0.280 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2018 | 241 | 0.270 |
Why?
|
Immune System | 5 | 2018 | 93 | 0.270 |
Why?
|
Carmustine | 1 | 2005 | 70 | 0.270 |
Why?
|
Enzyme Activation | 4 | 2014 | 692 | 0.270 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2018 | 182 | 0.270 |
Why?
|
Cell Separation | 3 | 2016 | 196 | 0.270 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2005 | 118 | 0.270 |
Why?
|
Protein Processing, Post-Translational | 3 | 2013 | 371 | 0.260 |
Why?
|
Antibody Formation | 2 | 2022 | 171 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 316 | 0.260 |
Why?
|
Tryptophan Oxygenase | 1 | 2004 | 8 | 0.260 |
Why?
|
Time Factors | 8 | 2020 | 5198 | 0.260 |
Why?
|
Lymphoid Tissue | 1 | 2005 | 57 | 0.260 |
Why?
|
Growth Inhibitors | 3 | 1989 | 41 | 0.260 |
Why?
|
Guanine | 1 | 2005 | 208 | 0.250 |
Why?
|
Disease Progression | 6 | 2018 | 1531 | 0.250 |
Why?
|
Benzimidazoles | 2 | 2016 | 140 | 0.250 |
Why?
|
Lymph Nodes | 6 | 2022 | 530 | 0.250 |
Why?
|
Skin | 2 | 2019 | 554 | 0.250 |
Why?
|
Biomarkers | 3 | 2022 | 1709 | 0.250 |
Why?
|
Brain Neoplasms | 3 | 2019 | 763 | 0.250 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2016 | 407 | 0.240 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 81 | 0.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2016 | 1196 | 0.240 |
Why?
|
Receptors, Interleukin-2 | 1 | 2003 | 66 | 0.240 |
Why?
|
Pyrroles | 2 | 2004 | 184 | 0.240 |
Why?
|
Genetic Vectors | 6 | 2007 | 438 | 0.240 |
Why?
|
Opportunistic Infections | 1 | 2004 | 59 | 0.240 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2010 | 112 | 0.230 |
Why?
|
fas Receptor | 1 | 2003 | 75 | 0.230 |
Why?
|
Lymphokines | 10 | 1995 | 76 | 0.230 |
Why?
|
Immunization | 6 | 2006 | 158 | 0.230 |
Why?
|
Interleukin-6 | 5 | 2020 | 255 | 0.230 |
Why?
|
Luciferases | 3 | 2012 | 118 | 0.230 |
Why?
|
Benzamides | 2 | 2014 | 226 | 0.230 |
Why?
|
Vaccination | 2 | 2022 | 253 | 0.230 |
Why?
|
Carcinoma, Basal Cell | 1 | 2023 | 54 | 0.230 |
Why?
|
Arthritis | 1 | 2023 | 46 | 0.230 |
Why?
|
Extracellular Traps | 1 | 2022 | 11 | 0.230 |
Why?
|
Transcription Factors | 2 | 2016 | 1555 | 0.220 |
Why?
|
Research | 2 | 2016 | 253 | 0.220 |
Why?
|
Promoter Regions, Genetic | 3 | 2012 | 937 | 0.220 |
Why?
|
Congresses as Topic | 3 | 2012 | 116 | 0.220 |
Why?
|
Piperidines | 3 | 2019 | 181 | 0.220 |
Why?
|
Administration, Oral | 3 | 2017 | 683 | 0.220 |
Why?
|
Cytoskeleton | 1 | 2004 | 192 | 0.220 |
Why?
|
RNA, Messenger | 7 | 2011 | 1975 | 0.220 |
Why?
|
Cell Line | 7 | 2006 | 2466 | 0.220 |
Why?
|
Adrenal Insufficiency | 1 | 2022 | 23 | 0.220 |
Why?
|
Lung Neoplasms | 5 | 2023 | 2260 | 0.220 |
Why?
|
MutS Homolog 2 Protein | 1 | 2022 | 30 | 0.220 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 55 | 0.210 |
Why?
|
Piperazines | 2 | 2014 | 272 | 0.210 |
Why?
|
Molecular Sequence Data | 9 | 2012 | 3029 | 0.210 |
Why?
|
Biological Specimen Banks | 1 | 2022 | 64 | 0.210 |
Why?
|
Drug Synergism | 4 | 2018 | 303 | 0.210 |
Why?
|
Internationality | 2 | 2012 | 69 | 0.210 |
Why?
|
RNA | 2 | 2022 | 560 | 0.210 |
Why?
|
Oligopeptides | 2 | 2001 | 179 | 0.200 |
Why?
|
Cell Nucleus | 1 | 2004 | 579 | 0.200 |
Why?
|
Pandemics | 3 | 2022 | 739 | 0.200 |
Why?
|
Bone Marrow Cells | 4 | 2003 | 253 | 0.200 |
Why?
|
Mastocytoma | 1 | 2001 | 4 | 0.200 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2013 | 689 | 0.200 |
Why?
|
src Homology Domains | 1 | 2001 | 44 | 0.200 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2022 | 683 | 0.200 |
Why?
|
Hematologic Neoplasms | 1 | 2004 | 329 | 0.200 |
Why?
|
Biopsy | 4 | 2019 | 1160 | 0.200 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2001 | 46 | 0.200 |
Why?
|
STAT1 Transcription Factor | 3 | 2011 | 52 | 0.200 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 241 | 0.200 |
Why?
|
Neurilemmoma | 1 | 2021 | 34 | 0.200 |
Why?
|
Antibodies, Viral | 1 | 2022 | 293 | 0.190 |
Why?
|
Carrier Proteins | 3 | 2016 | 672 | 0.190 |
Why?
|
Actins | 1 | 2004 | 448 | 0.190 |
Why?
|
Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 35 | 0.190 |
Why?
|
Transplantation Tolerance | 2 | 2018 | 130 | 0.190 |
Why?
|
Models, Immunological | 2 | 2015 | 80 | 0.190 |
Why?
|
Forkhead Transcription Factors | 2 | 2013 | 166 | 0.190 |
Why?
|
HSP40 Heat-Shock Proteins | 2 | 2012 | 18 | 0.190 |
Why?
|
Saliva | 1 | 2021 | 122 | 0.190 |
Why?
|
Lymphocyte Culture Test, Mixed | 3 | 2013 | 74 | 0.190 |
Why?
|
Biomedical Research | 2 | 2016 | 375 | 0.190 |
Why?
|
Government Agencies | 1 | 2020 | 10 | 0.190 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 104 | 0.180 |
Why?
|
Fever | 1 | 2020 | 125 | 0.180 |
Why?
|
Fluorescent Antibody Technique | 2 | 2011 | 314 | 0.180 |
Why?
|
C-Reactive Protein | 1 | 2020 | 190 | 0.180 |
Why?
|
Thrombosis | 1 | 2022 | 296 | 0.180 |
Why?
|
Herpesvirus 1, Human | 1 | 2022 | 244 | 0.180 |
Why?
|
Respiratory Muscles | 1 | 1999 | 13 | 0.180 |
Why?
|
Polymyositis | 1 | 1999 | 6 | 0.180 |
Why?
|
Societies, Medical | 3 | 2013 | 572 | 0.180 |
Why?
|
Octreotide | 1 | 1999 | 16 | 0.180 |
Why?
|
Informed Consent | 1 | 2022 | 266 | 0.180 |
Why?
|
Patient Care Planning | 1 | 2020 | 81 | 0.180 |
Why?
|
Thymoma | 1 | 1999 | 30 | 0.180 |
Why?
|
CRISPR-Cas Systems | 1 | 2020 | 70 | 0.180 |
Why?
|
MAP Kinase Kinase 4 | 2 | 2011 | 67 | 0.170 |
Why?
|
Growth Substances | 2 | 1990 | 80 | 0.170 |
Why?
|
Thymus Neoplasms | 1 | 1999 | 41 | 0.170 |
Why?
|
Antifungal Agents | 1 | 2020 | 117 | 0.170 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2019 | 103 | 0.170 |
Why?
|
Granzymes | 3 | 2006 | 92 | 0.170 |
Why?
|
Tumor Burden | 2 | 2017 | 288 | 0.170 |
Why?
|
Genes, myc | 2 | 2018 | 39 | 0.170 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2004 | 302 | 0.170 |
Why?
|
Interleukin-3 | 4 | 1994 | 36 | 0.170 |
Why?
|
Diet | 1 | 2022 | 442 | 0.170 |
Why?
|
Azetidines | 2 | 2019 | 36 | 0.170 |
Why?
|
Needs Assessment | 1 | 2020 | 154 | 0.170 |
Why?
|
Xanthones | 2 | 2015 | 11 | 0.170 |
Why?
|
Databases, Factual | 1 | 2022 | 808 | 0.170 |
Why?
|
Gene Targeting | 2 | 2013 | 72 | 0.170 |
Why?
|
Antibody Affinity | 1 | 2018 | 38 | 0.170 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1999 | 150 | 0.170 |
Why?
|
Carcinogenesis | 1 | 2020 | 194 | 0.160 |
Why?
|
Young Adult | 5 | 2019 | 5961 | 0.160 |
Why?
|
Bifidobacterium longum | 1 | 2018 | 2 | 0.160 |
Why?
|
CD4 Antigens | 7 | 2003 | 83 | 0.160 |
Why?
|
Chemoradiotherapy | 1 | 2020 | 301 | 0.160 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2017 | 8 | 0.160 |
Why?
|
Transcriptome | 2 | 2019 | 574 | 0.160 |
Why?
|
Advisory Committees | 3 | 2012 | 90 | 0.160 |
Why?
|
Enterococcus faecium | 1 | 2018 | 32 | 0.160 |
Why?
|
Chemokine CXCL9 | 1 | 2017 | 7 | 0.150 |
Why?
|
Neuroblastoma | 1 | 2021 | 374 | 0.150 |
Why?
|
Integrin alpha Chains | 1 | 2017 | 14 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 1073 | 0.150 |
Why?
|
Deoxyglucose | 2 | 2008 | 37 | 0.150 |
Why?
|
Fingolimod Hydrochloride | 1 | 2017 | 29 | 0.150 |
Why?
|
SOX9 Transcription Factor | 1 | 2016 | 23 | 0.150 |
Why?
|
Analysis of Variance | 2 | 2012 | 912 | 0.150 |
Why?
|
Proto-Oncogenes | 1 | 2016 | 61 | 0.150 |
Why?
|
Lymphocytes | 2 | 2004 | 461 | 0.150 |
Why?
|
Polymerase Chain Reaction | 3 | 2015 | 927 | 0.150 |
Why?
|
Extracellular Matrix | 1 | 2018 | 231 | 0.150 |
Why?
|
Liver | 3 | 2004 | 1229 | 0.150 |
Why?
|
HLA-A Antigens | 1 | 2016 | 44 | 0.150 |
Why?
|
Drug Approval | 2 | 2020 | 62 | 0.150 |
Why?
|
Protein Binding | 3 | 2022 | 1454 | 0.140 |
Why?
|
Antibodies | 2 | 2015 | 349 | 0.140 |
Why?
|
Survival Rate | 7 | 2020 | 1856 | 0.140 |
Why?
|
Metformin | 1 | 2018 | 128 | 0.140 |
Why?
|
Pyroptosis | 1 | 2016 | 2 | 0.140 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 21 | 0.140 |
Why?
|
Caspase 1 | 1 | 2016 | 18 | 0.140 |
Why?
|
I-kappa B Kinase | 1 | 2016 | 37 | 0.140 |
Why?
|
Survival Analysis | 5 | 2021 | 1536 | 0.140 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 455 | 0.140 |
Why?
|
Feces | 1 | 2018 | 316 | 0.140 |
Why?
|
Cytosol | 1 | 2016 | 189 | 0.140 |
Why?
|
Anemia | 2 | 2009 | 128 | 0.140 |
Why?
|
Cohort Studies | 4 | 2021 | 2759 | 0.140 |
Why?
|
PPAR gamma | 1 | 2016 | 66 | 0.140 |
Why?
|
Mice, Nude | 3 | 2018 | 790 | 0.140 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 458 | 0.140 |
Why?
|
DNA Damage | 1 | 2017 | 362 | 0.140 |
Why?
|
Immunotherapy, Active | 1 | 1995 | 15 | 0.140 |
Why?
|
Receptors, CXCR3 | 1 | 2015 | 12 | 0.140 |
Why?
|
Lymphatic Vessels | 1 | 2016 | 68 | 0.140 |
Why?
|
Patient Reported Outcome Measures | 1 | 2016 | 165 | 0.130 |
Why?
|
Leukemia L1210 | 4 | 2000 | 12 | 0.130 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 265 | 0.130 |
Why?
|
Peptide Fragments | 2 | 2009 | 460 | 0.130 |
Why?
|
Maximum Tolerated Dose | 3 | 2019 | 270 | 0.130 |
Why?
|
Phenotype | 4 | 2017 | 2375 | 0.130 |
Why?
|
Fecal Microbiota Transplantation | 1 | 2015 | 62 | 0.130 |
Why?
|
Skin Transplantation | 1 | 2016 | 172 | 0.130 |
Why?
|
Gene Knockout Techniques | 1 | 2015 | 77 | 0.130 |
Why?
|
Cluster Analysis | 1 | 2016 | 369 | 0.130 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2013 | 755 | 0.130 |
Why?
|
Macrophage Activation | 1 | 2015 | 45 | 0.130 |
Why?
|
Proto-Oncogene Proteins | 2 | 1995 | 645 | 0.130 |
Why?
|
Symbiosis | 1 | 2015 | 118 | 0.130 |
Why?
|
Complement System Proteins | 1 | 2015 | 81 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
Wnt Proteins | 1 | 2015 | 123 | 0.130 |
Why?
|
Adjuvants, Immunologic | 2 | 2001 | 166 | 0.120 |
Why?
|
Stromal Cells | 2 | 2013 | 142 | 0.120 |
Why?
|
Inositol Phosphates | 1 | 1994 | 16 | 0.120 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2014 | 93 | 0.120 |
Why?
|
Child | 4 | 2022 | 6913 | 0.120 |
Why?
|
Interleukins | 6 | 2006 | 132 | 0.120 |
Why?
|
Benzazepines | 1 | 2014 | 89 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 480 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2014 | 138 | 0.120 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 291 | 0.120 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 179 | 0.120 |
Why?
|
Sunlight | 1 | 2013 | 26 | 0.120 |
Why?
|
Histocompatibility Antigens Class II | 3 | 2016 | 158 | 0.110 |
Why?
|
Colony-Stimulating Factors | 2 | 1990 | 14 | 0.110 |
Why?
|
Genes, RAG-1 | 2 | 2006 | 13 | 0.110 |
Why?
|
Mucous Membrane | 1 | 2013 | 83 | 0.110 |
Why?
|
Gene Amplification | 1 | 2013 | 131 | 0.110 |
Why?
|
Recombinant Fusion Proteins | 2 | 2013 | 555 | 0.110 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 329 | 0.110 |
Why?
|
MART-1 Antigen | 2 | 2003 | 19 | 0.110 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2012 | 133 | 0.110 |
Why?
|
Classification | 1 | 2012 | 54 | 0.110 |
Why?
|
Immunoblotting | 1 | 2012 | 267 | 0.110 |
Why?
|
Genotype | 1 | 2017 | 1850 | 0.110 |
Why?
|
Immunohistochemistry | 3 | 2012 | 1752 | 0.110 |
Why?
|
Eye Neoplasms | 1 | 2012 | 27 | 0.110 |
Why?
|
Lymphoproliferative Disorders | 1 | 1992 | 107 | 0.110 |
Why?
|
Transplantation, Homologous | 4 | 2016 | 996 | 0.100 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 111 | 0.100 |
Why?
|
B7-2 Antigen | 5 | 2001 | 40 | 0.100 |
Why?
|
Spinal Cord Neoplasms | 1 | 2012 | 48 | 0.100 |
Why?
|
DNA Primers | 1 | 2012 | 542 | 0.100 |
Why?
|
Autoantibodies | 2 | 2023 | 267 | 0.100 |
Why?
|
Major Histocompatibility Complex | 3 | 2000 | 81 | 0.100 |
Why?
|
Mice, Inbred C3H | 4 | 2016 | 370 | 0.100 |
Why?
|
Disease-Free Survival | 4 | 2019 | 1203 | 0.100 |
Why?
|
Documentation | 1 | 2011 | 98 | 0.100 |
Why?
|
Point Mutation | 1 | 2012 | 246 | 0.100 |
Why?
|
Health Resources | 1 | 2011 | 76 | 0.100 |
Why?
|
Biological Therapy | 1 | 2011 | 45 | 0.100 |
Why?
|
Receptors, Interleukin-6 | 2 | 2020 | 17 | 0.100 |
Why?
|
MAP Kinase Signaling System | 1 | 2011 | 192 | 0.100 |
Why?
|
Spleen | 6 | 2003 | 430 | 0.100 |
Why?
|
Lymphocyte Count | 2 | 2016 | 94 | 0.090 |
Why?
|
Vaccines, Subunit | 1 | 2010 | 55 | 0.090 |
Why?
|
Binding Sites | 1 | 2013 | 1098 | 0.090 |
Why?
|
Isoantigens | 2 | 2002 | 66 | 0.090 |
Why?
|
Crosses, Genetic | 1 | 2010 | 171 | 0.090 |
Why?
|
Kv1.3 Potassium Channel | 1 | 2009 | 14 | 0.090 |
Why?
|
L-Selectin | 1 | 2009 | 16 | 0.090 |
Why?
|
Scorpion Venoms | 1 | 2009 | 25 | 0.090 |
Why?
|
Neurotoxins | 1 | 2009 | 49 | 0.090 |
Why?
|
Potassium Channel Blockers | 1 | 2009 | 64 | 0.090 |
Why?
|
Protein Kinase C-theta | 1 | 2009 | 16 | 0.090 |
Why?
|
Anorexia | 1 | 2009 | 30 | 0.090 |
Why?
|
gp100 Melanoma Antigen | 2 | 2006 | 12 | 0.090 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2009 | 15 | 0.090 |
Why?
|
Glutamate Carboxypeptidase II | 1 | 2009 | 8 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2016 | 1051 | 0.090 |
Why?
|
Organoplatinum Compounds | 1 | 2009 | 94 | 0.090 |
Why?
|
Protein Array Analysis | 1 | 2009 | 50 | 0.090 |
Why?
|
Immunoprecipitation | 1 | 2009 | 134 | 0.090 |
Why?
|
Internet | 1 | 2011 | 309 | 0.090 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 6 | 1993 | 95 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2010 | 177 | 0.090 |
Why?
|
Bryostatins | 2 | 2006 | 15 | 0.090 |
Why?
|
Models, Biological | 3 | 2018 | 1748 | 0.090 |
Why?
|
Caspases | 1 | 2009 | 155 | 0.090 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 78 | 0.090 |
Why?
|
Enzyme Induction | 2 | 2001 | 88 | 0.080 |
Why?
|
Taxoids | 1 | 2009 | 129 | 0.080 |
Why?
|
Drug Therapy, Combination | 3 | 2020 | 893 | 0.080 |
Why?
|
Transplantation Immunology | 3 | 2004 | 84 | 0.080 |
Why?
|
Rituximab | 2 | 2010 | 116 | 0.080 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 2 | 2019 | 56 | 0.080 |
Why?
|
Purine-Nucleoside Phosphorylase | 2 | 2006 | 23 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2019 | 3616 | 0.080 |
Why?
|
Medicare | 2 | 2022 | 404 | 0.080 |
Why?
|
Fatigue | 1 | 2009 | 174 | 0.080 |
Why?
|
Integrins | 1 | 2008 | 76 | 0.080 |
Why?
|
Multigene Family | 1 | 2009 | 202 | 0.080 |
Why?
|
Diarrhea | 1 | 2009 | 181 | 0.080 |
Why?
|
Immunoglobulins | 2 | 2004 | 148 | 0.080 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2008 | 26 | 0.080 |
Why?
|
Minocycline | 1 | 2008 | 15 | 0.080 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2008 | 36 | 0.080 |
Why?
|
Diterpenes | 1 | 2008 | 20 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2010 | 261 | 0.080 |
Why?
|
Patient Selection | 4 | 2016 | 685 | 0.080 |
Why?
|
Nausea | 1 | 2009 | 175 | 0.080 |
Why?
|
NFATC Transcription Factors | 2 | 2006 | 29 | 0.080 |
Why?
|
RNA, Untranslated | 1 | 2007 | 63 | 0.080 |
Why?
|
Protein Prenylation | 1 | 2007 | 9 | 0.080 |
Why?
|
Cell Survival | 2 | 2013 | 966 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2009 | 179 | 0.080 |
Why?
|
Mice, Inbred CBA | 4 | 1994 | 52 | 0.080 |
Why?
|
Ribonuclease, Pancreatic | 1 | 2007 | 24 | 0.080 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2001 | 203 | 0.080 |
Why?
|
Programmed Cell Death 1 Ligand 2 Protein | 2 | 2004 | 10 | 0.080 |
Why?
|
Methionine | 1 | 2007 | 66 | 0.080 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 363 | 0.070 |
Why?
|
Immune Sera | 2 | 2003 | 52 | 0.070 |
Why?
|
Ovalbumin | 3 | 2015 | 109 | 0.070 |
Why?
|
United States | 4 | 2022 | 6637 | 0.070 |
Why?
|
Double-Blind Method | 2 | 2022 | 1822 | 0.070 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2007 | 124 | 0.070 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2007 | 155 | 0.070 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 2 | 2005 | 100 | 0.070 |
Why?
|
Abdominal Neoplasms | 1 | 2006 | 39 | 0.070 |
Why?
|
Transcription, Genetic | 1 | 2010 | 1135 | 0.070 |
Why?
|
Severity of Illness Index | 2 | 2022 | 1796 | 0.070 |
Why?
|
Eukaryotic Initiation Factors | 1 | 2005 | 8 | 0.070 |
Why?
|
Concanavalin A | 3 | 1990 | 52 | 0.070 |
Why?
|
Carbon Monoxide | 1 | 2005 | 90 | 0.070 |
Why?
|
Transplantation Conditioning | 2 | 2005 | 373 | 0.070 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2006 | 148 | 0.070 |
Why?
|
High-Throughput Screening Assays | 2 | 2018 | 55 | 0.070 |
Why?
|
Pyridines | 1 | 2007 | 309 | 0.070 |
Why?
|
Cell Polarity | 1 | 2005 | 114 | 0.060 |
Why?
|
Cell-Free System | 3 | 1989 | 51 | 0.060 |
Why?
|
Receptors, Immunologic | 2 | 2004 | 135 | 0.060 |
Why?
|
Ionomycin | 3 | 1996 | 21 | 0.060 |
Why?
|
Biological Availability | 1 | 2004 | 92 | 0.060 |
Why?
|
Myeloid Differentiation Factor 88 | 2 | 2014 | 47 | 0.060 |
Why?
|
Graft vs Host Disease | 2 | 2004 | 364 | 0.060 |
Why?
|
Interphase | 2 | 2001 | 34 | 0.060 |
Why?
|
CD4-CD8 Ratio | 1 | 2004 | 18 | 0.060 |
Why?
|
Glycolysis | 1 | 2005 | 129 | 0.060 |
Why?
|
Plasma Membrane Calcium-Transporting ATPases | 1 | 2004 | 5 | 0.060 |
Why?
|
Cytochalasin D | 1 | 2004 | 14 | 0.060 |
Why?
|
Calcium-Transporting ATPases | 1 | 2004 | 29 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2004 | 307 | 0.060 |
Why?
|
Amino Acids | 1 | 2005 | 252 | 0.060 |
Why?
|
Ion Transport | 1 | 2004 | 81 | 0.060 |
Why?
|
Imatinib Mesylate | 2 | 2014 | 126 | 0.060 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2004 | 75 | 0.060 |
Why?
|
PC12 Cells | 1 | 2003 | 115 | 0.060 |
Why?
|
bcl-X Protein | 1 | 2003 | 52 | 0.060 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2004 | 63 | 0.060 |
Why?
|
Fas Ligand Protein | 1 | 2003 | 49 | 0.060 |
Why?
|
Adenocarcinoma | 2 | 2009 | 1160 | 0.060 |
Why?
|
Receptors, CCR7 | 1 | 2003 | 16 | 0.060 |
Why?
|
Chemokine CCL19 | 1 | 2003 | 10 | 0.060 |
Why?
|
Cell Membrane | 2 | 2004 | 664 | 0.060 |
Why?
|
Chemokine CCL21 | 1 | 2003 | 16 | 0.060 |
Why?
|
Receptors, Chemokine | 1 | 2003 | 31 | 0.060 |
Why?
|
Cation Transport Proteins | 1 | 2004 | 64 | 0.060 |
Why?
|
Chemokines, CC | 1 | 2003 | 34 | 0.060 |
Why?
|
Oxygen | 1 | 2008 | 725 | 0.060 |
Why?
|
Calcium Signaling | 1 | 2004 | 129 | 0.060 |
Why?
|
Breast Neoplasms | 1 | 2016 | 2881 | 0.060 |
Why?
|
Myeloid Cells | 1 | 2003 | 97 | 0.060 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2022 | 32 | 0.060 |
Why?
|
Risk Assessment | 2 | 2014 | 2253 | 0.060 |
Why?
|
Inflammation | 2 | 2020 | 913 | 0.060 |
Why?
|
Microsatellite Instability | 1 | 2022 | 40 | 0.060 |
Why?
|
Pathologists | 1 | 2022 | 24 | 0.050 |
Why?
|
Mice, Inbred Strains | 2 | 1995 | 305 | 0.050 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 40 | 0.050 |
Why?
|
Autoimmunity | 1 | 2004 | 160 | 0.050 |
Why?
|
Antigens | 1 | 2003 | 228 | 0.050 |
Why?
|
Angiotensin II | 1 | 2022 | 94 | 0.050 |
Why?
|
Cell Cycle Proteins | 1 | 2005 | 388 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2004 | 3347 | 0.050 |
Why?
|
Histocompatibility Antigen H-2D | 1 | 2001 | 5 | 0.050 |
Why?
|
Rats | 2 | 2009 | 3984 | 0.050 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.050 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 113 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2014 | 429 | 0.050 |
Why?
|
STAT6 Transcription Factor | 1 | 2000 | 28 | 0.050 |
Why?
|
Enterovirus | 1 | 2000 | 34 | 0.050 |
Why?
|
Viral Load | 1 | 2021 | 148 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2021 | 138 | 0.050 |
Why?
|
Antibodies, Blocking | 1 | 2000 | 21 | 0.050 |
Why?
|
Gene Transfer Techniques | 1 | 2000 | 152 | 0.050 |
Why?
|
Guidelines as Topic | 2 | 2011 | 162 | 0.050 |
Why?
|
RNA, Viral | 1 | 2021 | 327 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2020 | 118 | 0.050 |
Why?
|
Indicators and Reagents | 1 | 2000 | 72 | 0.050 |
Why?
|
Biotinylation | 1 | 2000 | 41 | 0.050 |
Why?
|
Immunoglobulin Variable Region | 1 | 2000 | 109 | 0.050 |
Why?
|
Recurrence | 2 | 2018 | 1137 | 0.050 |
Why?
|
Interleukin-1 | 2 | 1991 | 71 | 0.050 |
Why?
|
Muscle Fatigue | 1 | 1999 | 6 | 0.050 |
Why?
|
Paraneoplastic Syndromes | 1 | 1999 | 16 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2023 | 8431 | 0.040 |
Why?
|
Medical Oncology | 2 | 2013 | 357 | 0.040 |
Why?
|
Specific Pathogen-Free Organisms | 2 | 1997 | 74 | 0.040 |
Why?
|
Incidence | 1 | 2004 | 1568 | 0.040 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2000 | 112 | 0.040 |
Why?
|
Oncogene Proteins, Viral | 1 | 1999 | 34 | 0.040 |
Why?
|
Tracheostomy | 1 | 1999 | 42 | 0.040 |
Why?
|
Quantitative Trait Loci | 1 | 2023 | 576 | 0.040 |
Why?
|
Contrast Media | 1 | 2004 | 1076 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-fyn | 2 | 1995 | 24 | 0.040 |
Why?
|
Forecasting | 1 | 2000 | 303 | 0.040 |
Why?
|
Exosomes | 1 | 2019 | 50 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 450 | 0.040 |
Why?
|
Cell Compartmentation | 1 | 1998 | 69 | 0.040 |
Why?
|
Protein Stability | 1 | 2018 | 99 | 0.040 |
Why?
|
Papillomavirus Vaccines | 1 | 1999 | 58 | 0.040 |
Why?
|
Microglia | 1 | 2019 | 102 | 0.040 |
Why?
|
Thy-1 Antigens | 2 | 1995 | 16 | 0.040 |
Why?
|
Prospective Studies | 2 | 2019 | 4194 | 0.040 |
Why?
|
Systems Biology | 1 | 2018 | 42 | 0.040 |
Why?
|
Papillomaviridae | 1 | 1999 | 153 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 339 | 0.040 |
Why?
|
Pleura | 2 | 1972 | 30 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2019 | 162 | 0.040 |
Why?
|
Placenta Growth Factor | 1 | 2018 | 70 | 0.040 |
Why?
|
Sarcoma, Experimental | 1 | 1997 | 53 | 0.040 |
Why?
|
Adolescent | 4 | 2018 | 8968 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
Herpesviridae | 1 | 2017 | 14 | 0.040 |
Why?
|
Amino Acid Sequence | 4 | 2009 | 2062 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2009 | 1708 | 0.040 |
Why?
|
Acute Disease | 1 | 1999 | 824 | 0.040 |
Why?
|
Temperature | 1 | 2018 | 395 | 0.040 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2018 | 86 | 0.040 |
Why?
|
Metagenome | 1 | 2018 | 102 | 0.040 |
Why?
|
Spermatogonia | 1 | 1997 | 13 | 0.040 |
Why?
|
MDS1 and EVI1 Complex Locus Protein | 1 | 2016 | 6 | 0.040 |
Why?
|
Regulatory-Associated Protein of mTOR | 1 | 2016 | 11 | 0.040 |
Why?
|
Patient Safety | 1 | 2019 | 212 | 0.040 |
Why?
|
bcl-Associated Death Protein | 1 | 1996 | 16 | 0.040 |
Why?
|
Blood Pressure | 1 | 2022 | 1143 | 0.040 |
Why?
|
Osteonectin | 1 | 2016 | 22 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
Graft Survival | 2 | 2016 | 883 | 0.040 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 468 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 70 | 0.040 |
Why?
|
Interferon-alpha | 1 | 2017 | 233 | 0.040 |
Why?
|
MCF-7 Cells | 1 | 2016 | 106 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 1 | 2016 | 24 | 0.040 |
Why?
|
Respiration, Artificial | 1 | 1999 | 332 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 859 | 0.040 |
Why?
|
Consensus | 1 | 2018 | 333 | 0.040 |
Why?
|
Immunity, Active | 1 | 1996 | 9 | 0.040 |
Why?
|
Genes, ras | 1 | 1996 | 96 | 0.040 |
Why?
|
Lung | 1 | 2022 | 1167 | 0.040 |
Why?
|
CD47 Antigen | 1 | 2016 | 13 | 0.040 |
Why?
|
Lymphangiogenesis | 1 | 2016 | 38 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 476 | 0.040 |
Why?
|
Testis | 1 | 1997 | 152 | 0.040 |
Why?
|
Muromonab-CD3 | 1 | 1996 | 69 | 0.030 |
Why?
|
Heterografts | 1 | 2016 | 98 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 1996 | 84 | 0.030 |
Why?
|
Aminopyridines | 1 | 2015 | 32 | 0.030 |
Why?
|
Disease Management | 2 | 2013 | 327 | 0.030 |
Why?
|
Receptors, CCR5 | 1 | 2015 | 17 | 0.030 |
Why?
|
Hindlimb | 1 | 1996 | 89 | 0.030 |
Why?
|
Morpholines | 1 | 2015 | 65 | 0.030 |
Why?
|
Cell Transplantation | 1 | 1995 | 47 | 0.030 |
Why?
|
Cycloheximide | 1 | 1995 | 56 | 0.030 |
Why?
|
Protein Kinases | 1 | 1996 | 209 | 0.030 |
Why?
|
Pilot Projects | 1 | 2018 | 837 | 0.030 |
Why?
|
Receptors, CCR2 | 1 | 2015 | 35 | 0.030 |
Why?
|
Allografts | 1 | 2016 | 172 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2016 | 206 | 0.030 |
Why?
|
Leukocytes | 1 | 2016 | 202 | 0.030 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 2 | 1993 | 10 | 0.030 |
Why?
|
Receptors, Purinergic P2X7 | 1 | 2014 | 9 | 0.030 |
Why?
|
Interferon Regulatory Factor-3 | 1 | 2014 | 13 | 0.030 |
Why?
|
Toll-Like Receptor 9 | 1 | 2014 | 20 | 0.030 |
Why?
|
Histocompatibility Antigens | 2 | 1992 | 35 | 0.030 |
Why?
|
Risk Factors | 2 | 2021 | 5397 | 0.030 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2014 | 49 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2014 | 121 | 0.030 |
Why?
|
Toll-Like Receptor 4 | 1 | 2014 | 88 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 1995 | 646 | 0.030 |
Why?
|
Type C Phospholipases | 1 | 1994 | 28 | 0.030 |
Why?
|
Phosphotyrosine | 1 | 1994 | 32 | 0.030 |
Why?
|
Receptors, Notch | 1 | 2014 | 119 | 0.030 |
Why?
|
Tyrosine | 1 | 1994 | 133 | 0.030 |
Why?
|
RNA Interference | 1 | 2014 | 368 | 0.030 |
Why?
|
Cyclosporins | 2 | 1990 | 59 | 0.030 |
Why?
|
Protein Biosynthesis | 1 | 1995 | 378 | 0.030 |
Why?
|
GTP Phosphohydrolases | 1 | 2013 | 71 | 0.030 |
Why?
|
Mitochondria | 1 | 1996 | 535 | 0.030 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 1992 | 11 | 0.030 |
Why?
|
Exons | 1 | 2014 | 450 | 0.030 |
Why?
|
Citrus paradisi | 1 | 2012 | 5 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 547 | 0.030 |
Why?
|
Ketoconazole | 1 | 2012 | 25 | 0.030 |
Why?
|
NF-kappa B | 1 | 2016 | 442 | 0.030 |
Why?
|
Organ Transplantation | 1 | 2016 | 263 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 551 | 0.030 |
Why?
|
Pneumothorax | 1 | 1972 | 51 | 0.030 |
Why?
|
Hyperlipidemias | 1 | 2012 | 95 | 0.030 |
Why?
|
Access to Information | 1 | 2012 | 27 | 0.030 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1991 | 44 | 0.030 |
Why?
|
Muscle, Smooth | 1 | 1993 | 354 | 0.030 |
Why?
|
Drainage | 1 | 1972 | 157 | 0.030 |
Why?
|
Cervical Vertebrae | 1 | 2012 | 79 | 0.030 |
Why?
|
Colonic Neoplasms | 2 | 2007 | 554 | 0.030 |
Why?
|
International Cooperation | 1 | 2011 | 126 | 0.030 |
Why?
|
Hyperglycemia | 1 | 2012 | 176 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 1993 | 435 | 0.020 |
Why?
|
Awards and Prizes | 1 | 2011 | 36 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 429 | 0.020 |
Why?
|
ErbB Receptors | 1 | 2014 | 485 | 0.020 |
Why?
|
8-Bromo Cyclic Adenosine Monophosphate | 1 | 1990 | 13 | 0.020 |
Why?
|
Cholera Toxin | 1 | 1990 | 21 | 0.020 |
Why?
|
Phosphatidylinositols | 1 | 1990 | 21 | 0.020 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2010 | 50 | 0.020 |
Why?
|
Receptors, Fc | 1 | 1990 | 33 | 0.020 |
Why?
|
Immunologic Techniques | 1 | 1990 | 27 | 0.020 |
Why?
|
Dexamethasone | 1 | 1991 | 326 | 0.020 |
Why?
|
Biological Assay | 1 | 1990 | 78 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 1611 | 0.020 |
Why?
|
Blotting, Northern | 1 | 1990 | 256 | 0.020 |
Why?
|
Peptide Library | 1 | 2009 | 84 | 0.020 |
Why?
|
Chronic Disease | 1 | 2013 | 968 | 0.020 |
Why?
|
B-Cell CLL-Lymphoma 10 Protein | 1 | 2009 | 8 | 0.020 |
Why?
|
Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2009 | 6 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 1991 | 298 | 0.020 |
Why?
|
Xenopus laevis | 1 | 2009 | 137 | 0.020 |
Why?
|
STAT5 Transcription Factor | 1 | 2009 | 42 | 0.020 |
Why?
|
Drug Design | 1 | 2009 | 124 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 328 | 0.020 |
Why?
|
Physicians | 1 | 2016 | 672 | 0.020 |
Why?
|
Oocytes | 1 | 2009 | 220 | 0.020 |
Why?
|
Protein Engineering | 1 | 2009 | 140 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2009 | 94 | 0.020 |
Why?
|
Quality of Life | 1 | 2016 | 1575 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 850 | 0.020 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2007 | 14 | 0.020 |
Why?
|
Hematopoiesis | 1 | 1988 | 163 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 1992 | 788 | 0.020 |
Why?
|
Intestinal Diseases | 1 | 1967 | 79 | 0.020 |
Why?
|
Intestinal Obstruction | 1 | 1967 | 88 | 0.020 |
Why?
|
Bone Marrow | 1 | 1988 | 434 | 0.020 |
Why?
|
Interleukin-23 Subunit p19 | 1 | 2006 | 7 | 0.020 |
Why?
|
Jurkat Cells | 1 | 2006 | 77 | 0.020 |
Why?
|
Interleukin-23 | 1 | 2006 | 54 | 0.020 |
Why?
|
Treatment Failure | 1 | 2006 | 284 | 0.020 |
Why?
|
Models, Molecular | 1 | 2009 | 1284 | 0.020 |
Why?
|
Histocompatibility | 1 | 2005 | 71 | 0.020 |
Why?
|
Siblings | 1 | 2005 | 111 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 2594 | 0.020 |
Why?
|
Cause of Death | 1 | 2005 | 277 | 0.010 |
Why?
|
CHO Cells | 1 | 2003 | 187 | 0.010 |
Why?
|
Transplantation Chimera | 1 | 2003 | 79 | 0.010 |
Why?
|
Lactones | 1 | 2003 | 28 | 0.010 |
Why?
|
Macrolides | 1 | 2003 | 31 | 0.010 |
Why?
|
Gadolinium DTPA | 1 | 2004 | 261 | 0.010 |
Why?
|
Premedication | 1 | 2003 | 54 | 0.010 |
Why?
|
Brain | 1 | 1993 | 2211 | 0.010 |
Why?
|
Transgenes | 1 | 2003 | 180 | 0.010 |
Why?
|
Metacarpus | 1 | 1962 | 5 | 0.010 |
Why?
|
Osteoma, Osteoid | 1 | 1962 | 9 | 0.010 |
Why?
|
Osteoma | 1 | 1962 | 5 | 0.010 |
Why?
|
Integrin alphaXbeta2 | 1 | 2002 | 3 | 0.010 |
Why?
|
Cricetinae | 1 | 2003 | 560 | 0.010 |
Why?
|
Exudates and Transudates | 1 | 1962 | 14 | 0.010 |
Why?
|
Chyle | 1 | 1962 | 5 | 0.010 |
Why?
|
Chylothorax | 1 | 1962 | 7 | 0.010 |
Why?
|
Peritoneal Cavity | 1 | 1962 | 21 | 0.010 |
Why?
|
Chylous Ascites | 1 | 1962 | 9 | 0.010 |
Why?
|
Body Fluids | 1 | 1962 | 36 | 0.010 |
Why?
|
Radiography | 2 | 2001 | 812 | 0.010 |
Why?
|
ZAP-70 Protein-Tyrosine Kinase | 1 | 2001 | 18 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2002 | 62 | 0.010 |
Why?
|
Dimerization | 1 | 2001 | 143 | 0.010 |
Why?
|
Osteochondritis | 1 | 1961 | 2 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2004 | 448 | 0.010 |
Why?
|
Mesothelioma | 1 | 2004 | 309 | 0.010 |
Why?
|
Paclitaxel | 1 | 2003 | 460 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 2001 | 46 | 0.010 |
Why?
|
Thoracic Injuries | 1 | 1961 | 32 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2003 | 347 | 0.010 |
Why?
|
Self Mutilation | 1 | 1979 | 1 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2000 | 129 | 0.010 |
Why?
|
Parotitis | 1 | 1959 | 6 | 0.010 |
Why?
|
Syndrome | 1 | 1961 | 446 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2002 | 751 | 0.010 |
Why?
|
Enterostomy | 1 | 1959 | 3 | 0.010 |
Why?
|
Colostomy | 1 | 1959 | 13 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 1962 | 322 | 0.010 |
Why?
|
Papillomavirus E7 Proteins | 1 | 1999 | 31 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 1999 | 153 | 0.010 |
Why?
|
Foreign Bodies | 1 | 1979 | 63 | 0.010 |
Why?
|
Parietal Lobe | 1 | 1979 | 117 | 0.010 |
Why?
|
Anal Canal | 1 | 1959 | 89 | 0.010 |
Why?
|
Mice, Mutant Strains | 1 | 1998 | 229 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2004 | 731 | 0.010 |
Why?
|
Intestines | 1 | 2001 | 407 | 0.010 |
Why?
|
Surgical Procedures, Operative | 1 | 1959 | 182 | 0.010 |
Why?
|
Cell Lineage | 1 | 1998 | 273 | 0.010 |
Why?
|
Mandibular Diseases | 1 | 1956 | 16 | 0.010 |
Why?
|
GRB2 Adaptor Protein | 1 | 1996 | 9 | 0.010 |
Why?
|
ras Guanine Nucleotide Exchange Factors | 1 | 1996 | 8 | 0.010 |
Why?
|
Hypertrophy | 1 | 1956 | 62 | 0.010 |
Why?
|
Guanosine Triphosphate | 1 | 1996 | 38 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 1996 | 68 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 1996 | 74 | 0.010 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 85 | 0.010 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 1996 | 137 | 0.010 |
Why?
|
Hyperplasia | 1 | 1956 | 148 | 0.010 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 1996 | 73 | 0.010 |
Why?
|
Disease | 1 | 1956 | 90 | 0.010 |
Why?
|
Placenta | 1 | 1997 | 173 | 0.010 |
Why?
|
Mandible | 1 | 1956 | 119 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 1998 | 535 | 0.010 |
Why?
|
CD2 Antigens | 1 | 1993 | 22 | 0.010 |
Why?
|
Sex Factors | 1 | 1997 | 1053 | 0.010 |
Why?
|
CD5 Antigens | 1 | 1992 | 14 | 0.010 |
Why?
|
Methods | 1 | 1972 | 152 | 0.010 |
Why?
|
Leukocyte Common Antigens | 1 | 1992 | 46 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 1993 | 163 | 0.010 |
Why?
|
Lymphoma, B-Cell | 1 | 1991 | 103 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 1991 | 285 | 0.010 |
Why?
|
Pregnancy | 1 | 1997 | 2885 | 0.010 |
Why?
|
Postoperative Complications | 1 | 1959 | 2183 | 0.010 |
Why?
|
Macrophage-Activating Factors | 1 | 1987 | 2 | 0.010 |
Why?
|
Extracellular Space | 1 | 1987 | 90 | 0.000 |
Why?
|
Mice, Inbred A | 1 | 1984 | 23 | 0.000 |
Why?
|
Binding, Competitive | 1 | 1984 | 145 | 0.000 |
Why?
|
Formaldehyde | 1 | 1984 | 52 | 0.000 |
Why?
|
Polymers | 1 | 1984 | 202 | 0.000 |
Why?
|
Parietal Bone | 1 | 1979 | 20 | 0.000 |
Why?
|
Needles | 1 | 1979 | 35 | 0.000 |
Why?
|
Prisoners | 1 | 1979 | 40 | 0.000 |
Why?
|
Infant | 1 | 1962 | 3036 | 0.000 |
Why?
|